Femasys Regains Nasdaq Compliance

Femasys has received notice from Nasdaq informing that the company has regained compliance with the minimum bid price requirement under its Listing Rule 5550(a)(2).
 
This means Femasys has continued listing on the Nasdaq Capital Market and is now in compliance with all applicable listing standards, and common stock will continue to be listed on Nasdaq.
 
The company was previously notified of noncompliance with the minimum bid price rule on June 1 because common stock didn’t meet the closing bid price of $1 or more for 30 consecutive business days. The requirement was officially met on October 9, the required, tenth consecutive trading day when the common stock closing bid price was over $1.
 
Femasys aims to meet unmet needs for women’s health with a broad portfolio of in-office, accessible solutions. It’s FemBloc permanent birth control is in late-stage clinical development and received investigational device exemption approval from the FDA for its FINAL clinical trial of FemBloc earlier this year.
 
The company’s FemaSeed infertility treatment obtained FDA 510(k) clearance a few weeks ago. The intratubal insemination treatment claims to be less invasive than in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). The FemaSeed procedure works together with FemVue, its FDA-cleared diagnostic device for in-office ultrasound assessment of the fallopian tubes.
 

Check out an episode of editor-in-chief Sean Fenske’s “Medtech Matters” podcast with Femasys founder and CEO Kathy Lee-Sepsick here!